(57 days)
Frequency 55, Frequency 55 UV, Frequency 55 Aspheric, Encore, CooperFlex a 1. Onevue are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) in aphakic and not-aphakic persons with non-diseased eyes.
The lenses may be worn by persons who exhibit astigmatism of 2.00 diopters or less that does not interfere with usual acuity.
Frequency 55 lenses with UV absorbing monomer helps protect against transmission of harmful UV radiation to the cornea and into the eye.
- Encore Toric lenses are indicated for daily for the correction of refractive (myopia, hyperopia, and astigmatism) in aphakic and not-aphakic persons with nondiseased eyes. The lenses may be worn by persons who have astigmatism of 12.00 diopters or less.
Frequency 55, Frequency 55 Aspheric, Encore, CooperFlex and Onevue (methafilcon A) Soft (hydrophilic) Contact Lenses are available as spherical lenses. Encore Toric (methafilicon A) Soft (hydrophilic) Contact Lenses are available as astigmatic (toric) lenses. The lens material, methafilcon A, is a random copolymer of hydroxyethylmethacrylic acid. The lenses are tinted from edge to edge for visibility purposes with the color additive, Reactive Blue No. 4.
Frequency 55 UV (methafilcon A) Soft (hydrophilic) Contact Lenses are available as spherical lenses. The lens material, methafilcon A, is a random copolymer of hydroxyethylmethacrylate and methacrylic acid. A benzotriazole UV absorbing monomer is used to block UV radiation. the average transmittance characteristics are less than 10% in the UVB range if 280 to 315 nm and less than 10% in the UVA range of 315 to 380 nm. The lenses are tinted aqua from edge to edge for visibility purposes with the color additives, C.I. Reactive Blue No. 4 and C.I. Reactive Yellow 86.
I am sorry, but based on the provided text, there is no information about acceptance criteria, device performance, sample sizes for test or training sets, data provenance, expert involvement, adjudication methods, or MRMC studies.
The document is a 510(k) premarket notification for contact lenses. It states explicitly:
"No Non-Clinical or Clinical tests were performed. The lenses are the same as those cleared in the above premarket notifications."
Therefore, I cannot fulfill your request to describe the acceptance criteria and the study that proves the device meets them, as no such study was conducted for this specific submission. The approval is based on substantial equivalence to previously cleared devices.
{0}------------------------------------------------
- Submitter's Name:
NOV 2 4 1999
Image /page/0/Picture/2 description: The image shows the logo for CooperVision. The logo is black and white and features the company name in a stylized font. The "C" in Cooper is made up of two circles, one inside the other. The "n" in Vision is connected to a black square with a white "c" inside.
CooperVision, Inc. 711 North Road Scottsville, NY 14546 Phone: (716) 385-6810 FAX: (716) 889-5688
Bonnie Tsymbal Phone: (716) 264-3210 (716) 889-5688 FAX:
October 5, 1999
-
- Date Summary Prepared:
-
- Name of Device:
- Contact Person:
- Frequency 55 Trade Name: . Frequency 55 UV Frequency 55 Aspheric Encore Encore Toric CooperFlex Onevue . Common Name: Soft Contact Lens Soft Hydrophilic Contact Lens . Classification Name: (Per 21 CFR §886.5925) 5. Legally Marketed Device: Same as Trade Name
-
- Description of Device:
Frequency 55, Frequency 55 Aspheric, Encore, CooperFlex and Onevue (methafilcon A) Soft (hydrophilic) Contact Lenses are available as spherical lenses. Encore Toric (methafilicon A) Soft (hydrophilic) Contact Lenses are available as astigmatic (toric) lenses. The lens material, methafilcon A, is a random copolymer of hydroxyethylmethacrylic acid. The lenses are tinted from edge to edge for visibility purposes with the color additive, Reactive Blue No. 4.
Frequency 55 UV (methafilcon A) Soft (hydrophilic) Contact Lenses are available as spherical lenses. The lens material, methafilcon A, is a random copolymer of hydroxyethylmethacrylate and methacrylic acid. A benzotriazole UV absorbing monomer is used to block UV radiation. the average transmittance characteristics are less than 10% in the UVB range if 280 to 315 nm and less than 10% in the UVA range of 315 to 380 nm. The lenses are tinted aqua from edge to edge for visibility purposes with the color additives, C.I. Reactive Blue No. 4 and C.I. Reactive Yellow 86.
(716) 385-6810
Fax (716) 889-5688
{1}------------------------------------------------
-
- Intended Use:
Methafilcon A lenses are intended for use as a daily wear lens for the correction of refractive ametropia (myopic, hyperopic and astigmatism) in not-aphakic persons with non-diseased eyes.
- Intended Use:
-
- Summary of Non-Clinical/Clinical Tests:
No Non-Clinical or Clinical tests were performed. The lenses are the same as those cleared in the above premarket notifications.
- Summary of Non-Clinical/Clinical Tests:
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, which is a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus. The logo is in black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Nov 2 4 1999
Ms. Bonnie Tsymbal Coopervision, Inc. 711 North Road Scottsville, NY 14546
Re: K993252
Trade Name: Frequency 55, Frequency 55 UV, Frequency 55 Aspheric, Encore, Encore Tonc, CooperFlex and Onevue (methafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Regulatory Class: II Product Code: LPL, MVN (Disposable Use) Dated: November 5, 1999 Received: November 8, 1999
Dear Ms. Tsymbal:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{3}------------------------------------------------
Page 2 - Ms. Bonnie Tsymbal
. . This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours.
ARalph Rosenthal
A. Ralph Rosenthal, M.I Director Division of Ophthalmic Devices Office of Device Evaluation
Approval, it may be subject to such accurional controls. Existing major regulations arrecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{4}------------------------------------------------
Indication for Use Statement
| 510(k) Number: | K993252 |
|---|---|
| Device Name: | Frequency 55 |
| Frequency 55 UV | |
| Frequency 55 Aspheric | |
| Encore | |
| Encore Toric | |
| CooperFlex | |
| Onevue |
Indications for Use:
-
Frequency 55, Frequency 55 UV, Frequency 55 Aspheric, Encore, CooperFlex a 1. Onevue are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) in aphakic and not-aphakic persons with non-diseased eyes.
The lenses may be worn by persons who exhibit astigmatism of 2.00 diopters or less that does not interfere with usual acuity.
Frequency 55 lenses with UV absorbing monomer helps protect against transmission of harmful UV radiation to the cornea and into the eye. -
- Encore Toric lenses are indicated for daily for the correction of refractive (myopia, hyperopia, and astigmatism) in aphakic and not-aphakic persons with nondiseased eyes. The lenses may be worn by persons who have astigmatism of 12.00 diopters or less.
Frequent/Planned Replacement Wear
When prescribed for Frequent/Planned Replacement Wear, the Frequency 55, Frequency 55 Aspheric, Frequency 55 UV, Encore, Encore Toric, CooperFlex and Onevue lenses be cleaned, rinsed and disinfected each time they are removed from the eye and discarded
after the recommended wearing period prescribed by the eye care practitoner.
Disposable Wear
When prescribed for Disposable Wear, the wearing time prescribed by the eye practitioner is for daily wear (single use). Patients should be instructed to discard the lenses at each removal.
srfut
Prescription Use
(Per 21 CFR 801.109)
Division Sign-Off ision of Ophthalm Number K99
§ 886.5925 Soft (hydrophilic) contact lens.
(a)
Identification. A soft (hydrophilic) contact lens is a device intended to be worn directly against the cornea and adjacent limbal and scleral areas of the eye to correct vision conditions or act as a therapeutic bandage. The device is made of various polymer materials the main polymer molecules of which absorb or attract a certain volume (percentage) of water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.